Literature DB >> 7852294

The synthetic pathway for glucosylsphingosine in cultured fibroblasts.

Y Yamaguchi1, N Sasagasako, I Goto, T Kobayashi.   

Abstract

The synthesis of glucosylsphingosine (GlcSph), a glucosylceramide (GlcCer) analogue devoid of fatty acids, in cultured fibroblasts was studied by using conduritol beta epoxide (CBE), an inhibitor of beta-glucosidase, and 1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP), an inhibitor of glucosylceramide (GlcCer) synthase (glucosyltransferase). When CBE was added to the culture medium, the intracellular beta-glucosidase activity decreased, and both GlcCer and GlcSph accumulated in the cells. After the addition of PDMP, the concentration of GlcCer decreased, while the content of GlcSph increased. When CBE and PDMP were added together, the intracellular accumulation of GlcSph to decreased to less than when CBE alone was added. Based on these results, the synthetic pathway for GlcSph was thus considered to not only be through the glucosylation of sphingosine, but also through the deacylation of GlcCer. When GlcCer (d18:1, C12:0) was added to the culture medium, the intracellular accumulation of GlcSph (d18:1) was evident, and it was also more pronounced in the presence of CBE. In addition, when GlcCer (d18:0, C12:0) was used, apparent accumulation of GlcSph (d18:0) was also observed. In order to determine whether or not the deacylase of GlcCer is identical to acid ceramidase, a deacylase of ceramide, the same experiments were carried out using fibroblasts from two patients with Farber disease, in which acid ceramidase is genetically deficient. The accumulation of GlcSph in the Farber disease fibroblasts after the loading of GlcCer for 7 days was found to be one-fifth of the control level.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7852294     DOI: 10.1093/oxfordjournals.jbchem.a124584

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  19 in total

1.  Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease.

Authors:  Pramod K Mistry; Jun Liu; Li Sun; Wei-Lien Chuang; Tony Yuen; Ruhua Yang; Ping Lu; Kate Zhang; Jianhua Li; Joan Keutzer; Agnes Stachnik; Albert Mennone; James L Boyer; Dhanpat Jain; Roscoe O Brady; Maria I New; Mone Zaidi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-17       Impact factor: 11.205

2.  Acid ceramidase inhibition ameliorates α-synuclein accumulation upon loss of GBA1 function.

Authors:  Myung Jong Kim; Sohee Jeon; Lena F Burbulla; Dimitri Krainc
Journal:  Hum Mol Genet       Date:  2018-06-01       Impact factor: 6.150

3.  Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response.

Authors:  Nick Dekker; Laura van Dussen; Carla E M Hollak; Herman Overkleeft; Saskia Scheij; Karen Ghauharali; Mariëlle J van Breemen; Maria J Ferraz; Johanna E M Groener; Mario Maas; Frits A Wijburg; Dave Speijer; Anna Tylki-Szymanska; Pramod K Mistry; Rolf G Boot; Johannes M Aerts
Journal:  Blood       Date:  2011-08-25       Impact factor: 22.113

4.  Glucosylceramide transfer from lysosomes--the missing link in molecular pathology of glucosylceramidase deficiency: a hypothesis based on existing data.

Authors:  M Elleder
Journal:  J Inherit Metab Dis       Date:  2006-11-02       Impact factor: 4.982

5.  Glucosylsphingosine is a key biomarker of Gaucher disease.

Authors:  Vagishwari Murugesan; Wei-Lien Chuang; Jun Liu; Andrew Lischuk; Katherine Kacena; Haiqun Lin; Gregory M Pastores; Ruhua Yang; Joan Keutzer; Kate Zhang; Pramod K Mistry
Journal:  Am J Hematol       Date:  2016-08-08       Impact factor: 10.047

6.  Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target.

Authors:  Yedda Li; Yue Xu; Bruno A Benitez; Murtaza S Nagree; Joshua T Dearborn; Xuntian Jiang; Miguel A Guzman; Josh C Woloszynek; Alex Giaramita; Bryan K Yip; Joseph Elsbernd; Michael C Babcock; Melanie Lo; Stephen C Fowler; David F Wozniak; Carole A Vogler; Jeffrey A Medin; Brett E Crawford; Mark S Sands
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-16       Impact factor: 11.205

7.  Substrate Reduction Therapy for Sandhoff Disease through Inhibition of Glucosylceramide Synthase Activity.

Authors:  John Marshall; Jennifer B Nietupski; Hyejung Park; James Cao; Dinesh S Bangari; Cristina Silvescu; Terry Wilper; Kristen Randall; Drew Tietz; Bing Wang; Xiaoyou Ying; John P Leonard; Seng H Cheng
Journal:  Mol Ther       Date:  2019-06-04       Impact factor: 11.454

8.  Elevated glucosylsphingosine in Gaucher disease induced pluripotent stem cell neurons deregulates lysosomal compartment through mammalian target of rapamycin complex 1.

Authors:  Manasa P Srikanth; Jace W Jones; Maureen Kane; Ola Awad; Tea Soon Park; Elias T Zambidis; Ricardo A Feldman
Journal:  Stem Cells Transl Med       Date:  2021-03-03       Impact factor: 6.940

9.  Ubiquitous transgene expression of the glucosylceramide-synthesizing enzyme accelerates glucosylceramide accumulation and storage cells in a Gaucher disease mouse model.

Authors:  Sonya Barnes; You-Hai Xu; Wujuan Zhang; Benjamin Liou; Kenneth D R Setchell; Liming Bao; Gregory A Grabowski; Ying Sun
Journal:  PLoS One       Date:  2014-12-31       Impact factor: 3.240

10.  Action myoclonus-renal failure syndrome: diagnostic applications of activity-based probes and lipid analysis.

Authors:  Paulo Gaspar; Wouter W Kallemeijn; Anneke Strijland; Saskia Scheij; Marco Van Eijk; Jan Aten; Herman S Overkleeft; Andrea Balreira; Friederike Zunke; Michael Schwake; Clara Sá Miranda; Johannes M F G Aerts
Journal:  J Lipid Res       Date:  2013-11-08       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.